Guidant Transfers Accounts To Novoste, Exits Vascular Brachytherapy
This article was originally published in The Gray Sheet
Executive Summary
Guidant will terminate production of its Galileo intravascular radiotherapy system and exit the vascular brachytherapy (VBT) market altogether over the next six months, the firm announced April 22